An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson's Disease and G2019S LRRK2 Cohorts

Overview

Journal J Parkinsons Dis

Publisher Sage Publications

Specialty Neurology

Date 2020 Feb 3

PMID 32007961

Citations 24

Authors

Shalini Padmanabhan

Thomas A Lanz

Donal Gorman

Michele Wolfe

Alison Joyce

Carlos Cabrera

Rosemary Lawrence-Henderson

Najah Levers

Neal Joshi

Thong C Ma

Christopher Liong

Sushma Narayan

Roy N Alcalay

Samantha J Hutten

Marco A S Baptista

Kalpana Merchant

Affiliations

Soon will be listed here.

Abstract

The phosphorylated form of LRRK2, pS935 LRRK2, has been proposed as a target modulation biomarker for LRRK2 inhibitors. The primary aim of the study was to characterize and qualify this biomarker for therapeutic trials of LRRK2 inhibitors in Parkinson's disease (PD). To this end, analytically validated assays were used to monitor levels of pS935 LRRK2 and total LRRK2 in peripheral blood mononuclear cells (PBMCs) from the following donor groups: healthy controls, idiopathic PD, and G2019S carriers with and without PD. Neither analyte correlated with age, gender, or disease severity. While total LRRK2 levels were similar across the four groups, there was a significant reduction in pS935 LRRK2 levels in disease-manifesting G2019S carriers compared to idiopathic PD. In aggregate, these data indicate that phosphorylation of LRRK2 at S935 may reflect a state marker for G2019S LRRK2-driven PD, the underlying biology for which requires investigation in future studies. This study also provides critical foundational data to inform the integration of pS935 and total LRRK2 levels as biomarkers in therapeutic trials of LRRK2 kinase inhibitors.

Citing Articles

Genetic mutations in kinases: a comprehensive review on marketed inhibitors and unexplored targets in Parkinson's disease.

Raza A, Raina J, Sahu S, Wadhwa P Neurol Sci. 2025; .

PMID: 39760821 DOI: 10.1007/s10072-024-07970-2.

Unraveling the Ties: Type 2 Diabetes and Parkinson's Disease - A Nano-Based Targeted Drug Delivery Approach.

De S, Banerjee S, Rakshit P, Banerjee S, Kumar S Curr Diabetes Rev. 2024; 21(6):32-58.

PMID: 38747222 DOI: 10.2174/0115733998291968240429111357.

Post-translational modification and mitochondrial function in Parkinson's disease.

Luo S, Wang D, Zhang Z Front Mol Neurosci. 2024; 16:1329554.

PMID: 38273938 PMC: 10808367. DOI: 10.3389/fnmol.2023.1329554.

A potential patient stratification biomarker for Parkinson´s disease based on LRRK2 kinase-mediated centrosomal alterations in peripheral blood-derived cells.

Naaldijk Y, Fernandez B, Fasiczka R, Fdez E, Leghay C, Croitoru I NPJ Parkinsons Dis. 2024; 10(1):12.

PMID: 38191886 PMC: 10774440. DOI: 10.1038/s41531-023-00624-8.

LRRK2 phosphorylation status and kinase activity regulate (macro)autophagy in a Rab8a/Rab10-dependent manner.

Kania E, Long J, McEwan D, Welkenhuyzen K, La Rovere R, Luyten T Cell Death Dis. 2023; 14(7):436.

PMID: 37454104 PMC: 10349885. DOI: 10.1038/s41419-023-05964-0.

References

Alcalay R, Levy O, Waters C, Fahn S, Ford B, Kuo S . Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. Brain. 2015; 138(Pt 9):2648-58. PMC: 4564023. DOI: 10.1093/brain/awv179. View

Cook D, Kannarkat G, Cintron A, Butkovich L, Fraser K, Chang J . LRRK2 levels in immune cells are increased in Parkinson's disease. NPJ Parkinsons Dis. 2017; 3:11. PMC: 5459798. DOI: 10.1038/s41531-017-0010-8. View

Dzamko N, Chua G, Ranola M, Rowe D, Halliday G . Measurement of LRRK2 and Ser910/935 phosphorylated LRRK2 in peripheral blood mononuclear cells from idiopathic Parkinson's disease patients. J Parkinsons Dis. 2013; 3(2):145-52. DOI: 10.3233/JPD-130174. View

Henderson M, Sengupta M, McGeary I, Zhang B, Olufemi M, Brown H . LRRK2 inhibition does not impart protection from α-synuclein pathology and neuron death in non-transgenic mice. Acta Neuropathol Commun. 2019; 7(1):28. PMC: 6391792. DOI: 10.1186/s40478-019-0679-5. View

Fan Y, Howden A, Sarhan A, Lis P, Ito G, Martinez T . Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils. Biochem J. 2017; 475(1):23-44. PMC: 5748842. DOI: 10.1042/BCJ20170803. View

Fell M, Mirescu C, Basu K, Cheewatrakoolpong B, DeMong D, Ellis J . MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition. J Pharmacol Exp Ther. 2015; 355(3):397-409. DOI: 10.1124/jpet.115.227587. View

Paisan-Ruiz C, Jain S, Evans E, Gilks W, Simon J, van der Brug M . Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron. 2004; 44(4):595-600. DOI: 10.1016/j.neuron.2004.10.023. View

Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S . Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004; 44(4):601-7. DOI: 10.1016/j.neuron.2004.11.005. View

Hughes A, Daniel S, Kilford L, Lees A . Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992; 55(3):181-4. PMC: 1014720. DOI: 10.1136/jnnp.55.3.181. View

10.

Nichols R, Dzamko N, Morrice N, Campbell D, Deak M, Ordureau A . 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem J. 2010; 430(3):393-404. PMC: 2932554. DOI: 10.1042/BJ20100483. View

11.

Nichols R . LRRK2 Phosphorylation. Adv Neurobiol. 2017; 14:51-70. DOI: 10.1007/978-3-319-49969-7_3. View

12.

Atashrazm F, Hammond D, Perera G, Bolliger M, Matar E, Halliday G . LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients. Mov Disord. 2019; 34(3):406-415. DOI: 10.1002/mds.27601. View

13.

Longo F, Russo I, Shimshek D, Greggio E, Morari M . Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging. Neurobiol Dis. 2014; 71:62-73. PMC: 4194318. DOI: 10.1016/j.nbd.2014.07.013. View

14.

Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A . Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis. 2006; 23(2):329-41. DOI: 10.1016/j.nbd.2006.04.001. View

15.

Dzamko N, Gysbers A, Bandopadhyay R, Bolliger M, Uchino A, Zhao Y . LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies. Mov Disord. 2016; 32(3):423-432. DOI: 10.1002/mds.26892. View

16.

Perera G, Ranola M, Rowe D, Halliday G, Dzamko N . Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker. Sci Rep. 2016; 6:31391. PMC: 4977566. DOI: 10.1038/srep31391. View

17.

Domingo A, Klein C . Genetics of Parkinson disease. Handb Clin Neurol. 2018; 147:211-227. DOI: 10.1016/B978-0-444-63233-3.00014-2. View

18.

Steger M, Tonelli F, Ito G, Davies P, Trost M, Vetter M . Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases. Elife. 2016; 5. PMC: 4769169. DOI: 10.7554/eLife.12813. View

19.

Fuji R, Flagella M, Baca M, Baptista M, Brodbeck J, Chan B . Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Sci Transl Med. 2015; 7(273):273ra15. DOI: 10.1126/scitranslmed.aaa3634. View

20.

Reynolds A, Doggett E, Riddle S, Lebakken C, Nichols R . LRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site status. Front Mol Neurosci. 2014; 7:54. PMC: 4068021. DOI: 10.3389/fnmol.2014.00054. View